The association of human parvovirus B19 (PVB19) infection with the development of several systemic autoimmune diseases has been confirmed in other studies. To determine if there is any association of PVB19 infection with multiple sclerosis (MS), we studied the prevalence of serum anti-PVB19 IgG and IgM by an enzyme-linked immunosorbent assay and PVB19-specific DNA in the cerebrospinal fluid (CSF) by the polymerase chain reaction method in a total of 46 patients during exacerbation or remission of MS. Anti-PVB19 IgG was detected in 65.8% of the patients’ sera. The percentage was significantly higher than that in age-matched healthy control subjects (40%; p = 0.019), but was not higher in patients with other neurological diseases (50%; p = 0.16). There was no correlation between serum anti-PVB19 IgG status and antinuclear antibodies or oligoclonal IgG bands in CSF. Serum anti-PVB19 IgM and PVB19 DNA in CSF were consistently negative in the patients during exacerbation of MS. Although MS patients may be commonly infected with PVB19, our results suggest that there is no active PVB19 infection during exacerbation of MS.

Keywords:
Parvovirus B19, Multiple sclerosis, Polymerase chain reaction, Enzyme-linked immunosorbent assay
1.
Anderson LJ: Human parvoviruses. J Infect Dis 1990;161:603–608.
2.
Fawaz-Estrup F: Human parvovirus infection: Rheumatic manifestations, angioedema, C1 esterase inhibitor deficiency, ANA appearance, and possible onset of systemic lupus erythematosus. J Rheumatol 1996;23:1180–1185.
3.
Soloninka CA, Anderson MJ, Laskin CA: Anti-DNA and antilymphocyte antibodies during acute infection with human parvovirus B19. J Rheumatol 1989;16:777–781.
4.
Wagner AD, Goronzy JJ, Matteson EL, Weyand CM: Systemic monocyte and T-cell activation in a patient with human parvovirus B19 infection. Mayo Clin Proc 1995;70:261–265.
5.
Watanabe T, Satoh M, Oda Y: Human parvovirus B19 encephalopathy. Arch Dis Child 1994;70:71.
6.
Okumura A, Ichikawa T: Aseptic meningitis caused by human parvovirus B19. Arch Dis Child 1993;68:784–785.
7.
Durigon EL, Erdman DD, Gary W, Pallansch MA, Torok TJ, Anderson LJ: Multiple primer pairs for polymerase chain reaction (PCR) amplification of human parvovirus B19 DNA. J Virol Methods 1993;44:155–165.
8.
Shade RO, Blundell MC, Cotmore SF, Tattersall P, Astell CR: Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J Virol 1986;58:921–936.
9.
Cook SD, Rohowsky-Kochan C, Bansil S, Dowling PC: Evidence for a viral etiology of multiple sclerosis; in Cook SD (ed): Handbook of Multiple Sclerosis. New York, Dekker, 1996, pp 97–118.
10.
Fujinami RS, Oldstone MB: Amino acid homology between the encephalitogenic site of myelin basic protein and virus: Mechanism for autoimmunity. Science 1985;230:1043–1045.
11.
Alvord EC Jr, Jahnke U, Fischer EH, Kies MW, Driscoll BF, Compston DA: The multiple causes of multiple sclerosis: The importance of infections in childhood. J Child Neurol 1987;2:313–321.
12.
Nikkari S, Roivainen A, Hannonen P, Möttönen T, Luukkainen R, Yli-Jama T: Persistence of parvovirus B19 in synovial fluid and bone marrow. Ann Rheum Dis 1995;54:597–600.
13.
Haseyama K, Kudoh T, Yoto Y, Suzuki N, Chiba S: Detection of human parvovirus B19 DNA in cerebrospinal fluid. Pediatr Infect Dis J 1997;16:324–325.
14.
Collard RC, Koehler RP, Mattson DH: Frequency and significance of antinuclear antibodies in multiple sclerosis. Neurology 1997;49:857–861.
15.
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW: New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13:227–231.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.